Victrelis is owned by Merck Sharp Dohme.
Victrelis contains Boceprevir.
Victrelis has a total of 3 drug patents out of which 0 drug patents have expired.
Victrelis was authorised for market use on 13 May, 2011.
Victrelis is available in capsule;oral dosage forms.
Victrelis can be used as treatment of chronic hepatitis c (chc) genotype 1 infection, administered with food, treatment of chronic hepatitis c (chc) genotype 1 infection in combination with peginterferon alfa and ribavirin in adult patients (>=18 years of age) with compensated liver disease.
The generics of Victrelis are possible to be released after 11 November, 2027.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.|
|USRE43298||MERCK SHARP DOHME||Peptides as NS3-serine protease inhibitors of hepatitis C virus|| |
(1 year, 8 months from now)
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US8119602||MERCK SHARP DOHME||Administration of HCV protease inhibitors in combination with food to improve bioavailability|| |
(3 years from now)
|US7772178||MERCK SHARP DOHME||Pharmaceutical formulations and methods of treatment using the same|| |
(4 years from now)
Drugs and Companies using BOCEPREVIR ingredient
Market Authorisation Date: 13 May, 2011
Treatment: Treatment of chronic hepatitis c (chc) genotype 1 infection, administered with food; Treatment of chronic hepatitis c (chc) genotype 1 infection in combination with peginterferon alfa and ribavirin in...
Taiwan, Province of China
Korea, Republic of
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic